Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Targher

Showing results (51-60 of 638) with videos related to

Pageof 64
Sort By:
Diabetes Care|April 28, 2004
Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complicationsGiovanni Targher, Giacomo Zoppini
Alimentary Pharmacology & Therapeutics|June 24, 2022
Editorial: higher levels of certain serum bile acids in non-alcoholic fatty liver disease-new insights from GuatemalaAlessandro Mantovani, Giovanni Targher
Chest|June 25, 2008
Natriuretic peptides for assessing the prognosis of acute pulmonary embolismGiuseppe Lippi, Giovanni Targher
Digestive Diseases and Sciences|December 11, 2019
Cardiovascular Risk in NAFLD: An Intimate Relationship?Amedeo Lonardo, Giovanni Targher
Hepatobiliary Surgery and Nutrition|August 25, 2021
Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutideAlessandro Mantovani, Giovanni Targher
Hepatology (Baltimore, Md.)|September 10, 2010
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular diseaseGiovanni Targher, Christopher P Day
Journal of Hepatology|April 29, 2015
NAFLD: a multisystem diseaseChristopher D Byrne, Giovanni Targher
Journal of Hepatology|February 16, 2020
NAFLD as a driver of chronic kidney diseaseChristopher D Byrne, Giovanni Targher
The Journal of Clinical Endocrinology and Metabolism|January 8, 2013
Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complicationsGiovanni Targher, Christopher D Byrne
Nature Reviews. Gastroenterology & Hepatology|June 30, 2016
Obesity: Metabolically healthy obesity and NAFLDGiovanni Targher, Christopher D Byrne
Pageof 64

Showing results (51-60 of 638) with videos related to

Sort By:
Pageof 64
Diabetes Care|April 28, 2004
Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complicationsGiovanni Targher, Giacomo Zoppini
Alimentary Pharmacology & Therapeutics|June 24, 2022
Editorial: higher levels of certain serum bile acids in non-alcoholic fatty liver disease-new insights from GuatemalaAlessandro Mantovani, Giovanni Targher
Chest|June 25, 2008
Natriuretic peptides for assessing the prognosis of acute pulmonary embolismGiuseppe Lippi, Giovanni Targher
Digestive Diseases and Sciences|December 11, 2019
Cardiovascular Risk in NAFLD: An Intimate Relationship?Amedeo Lonardo, Giovanni Targher
Hepatobiliary Surgery and Nutrition|August 25, 2021
Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutideAlessandro Mantovani, Giovanni Targher
Hepatology (Baltimore, Md.)|September 10, 2010
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular diseaseGiovanni Targher, Christopher P Day
Journal of Hepatology|April 29, 2015
NAFLD: a multisystem diseaseChristopher D Byrne, Giovanni Targher
Journal of Hepatology|February 16, 2020
NAFLD as a driver of chronic kidney diseaseChristopher D Byrne, Giovanni Targher
The Journal of Clinical Endocrinology and Metabolism|January 8, 2013
Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complicationsGiovanni Targher, Christopher D Byrne
Nature Reviews. Gastroenterology & Hepatology|June 30, 2016
Obesity: Metabolically healthy obesity and NAFLDGiovanni Targher, Christopher D Byrne
Pageof 64